
The CryoSpray Ablation System AND the truFreeze® System have not been cleared by the US Food and Drug Administration for each of the specific clinical application(s) described in these articles. CSA Medical manufactures and markets the spray cryotherapy devices described in these publications.

The truFreeze® System is intended for cryogenic destruction of tissue using Liquid Nitrogen spray that has a boiling point of -196°C requiring either active or passive venting during surgical procedures. The truFreeze® System is indicated for use as a cryosurgical tool in the fields of dermatology, gynecology, and general surgery, to ablate benign (e.g., Barrett’s Esophagus with high dysplasia and/or low grade dysplasia) and malignant lesions.


The CryoSpray Ablation System AND the truFreeze® System have not been cleared by the US Food and Drug Administration for each of the specific clinical application(s) described in these articles. CSA Medical manufactures and markets the spray cryotherapy devices described in these publications.

The truFreeze® System is intended for cryogenic destruction of tissue using Liquid Nitrogen spray that has a boiling point of -196°C requiring either active or passive venting during surgical procedures. The truFreeze® System is indicated for use as a cryosurgical tool in the fields of dermatology, gynecology, and general surgery, to ablate benign (e.g., Barrett’s Esophagus with high dysplasia and/or low grade dysplasia) and malignant lesions.